Deal facts
- Buyer
- Altaris, LLC
- Target
- Simulations Plus, Inc.
- Deal value
- Not disclosed
- Announced
- 16 June 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash
Sources
Altaris, LLC has agreed to acquire Simulations Plus, Inc. in a cash transaction that will take the healthcare company private. The deal was announced on 16 June 2026 and subsequently completed on 6 October 2026. Both the buyer and the target are based in the United States. The consideration for the acquisition is structured entirely in cash. No specific headline offer value was reported for this transaction. The sector is identified as healthcare. The transaction status is recorded as completed.
The acquisition of Simulations Plus, Inc. by Altaris, LLC represents a significant shift in the ownership structure of the firm. As a going-private deal, the company will no longer be publicly traded following the completion of the transaction. The process from announcement to completion spanned approximately four months. The final status confirms that the deal has been fully executed. There are no further regulatory approvals or pending conditions noted in the available facts. The transaction is concluded.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
Altaris, LLC completes acquisition of Simulations Plus, Inc.
EX-99.1 4 closingpr.htm EX-99.1 closingpr 1 Exhibit 99.1 Simulations Plus Announces Completion of Acquisition by Altaris RESEARCH TRIANGLE PARK, NC, October 6, 2026 – Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the completion of its acquisition b
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
ArcheNova Technology Co., Ltd to acquire ArcheNova Biotech Corp.
ArcheNova Technology Co., Ltd has agreed to acquire ArcheNova Biotech Corp. in a transaction valued at two billion US dollars. The deal, announced on 13 October 2026, in…
- Buyer
- ArcheNova Technology Co., Ltd
- Target
- ArcheNova Biotech Corp.
- Deal value
- USD 2,000,000,000
- Deal type
- going private
Onyx Bidco LLC to acquire Option Care Health, Inc.
Onyx Bidco LLC has agreed to acquire Option Care Health, Inc. in a cash transaction. The deal, announced on 5 October 2026, involves the US-based buyer purchasing the US…
- Buyer
- Onyx Bidco LLC
- Target
- Option Care Health, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Lifecore Inc. to acquire Lifecore Biomedical, Inc.
Lifecore Inc. has agreed to acquire Lifecore Biomedical, Inc. in a transaction designed to take the healthcare company private. The deal was announced on 28 September 20…
- Buyer
- Lifecore Inc.
- Target
- Lifecore Biomedical, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
TULIP UK BIDCO LIMITED to acquire Spire Healthcare Group plc
TULIP UK BIDCO LIMITED has agreed to acquire Spire Healthcare Group plc in a going private transaction valued at approximately GBP 1.0265 billion. The deal structure inv…
- Buyer
- TULIP UK BIDCO LIMITED
- Target
- Spire Healthcare Group plc
- Deal value
- GBP 1,026,500,000
- Deal type
- going private
Curium US Holdings LLC to acquire Lantheus Holdings, Inc.
Curium US Holdings LLC has agreed to acquire Lantheus Holdings, Inc. in a transaction designed to take the healthcare company private. The deal was announced on 3 August…
- Buyer
- Curium US Holdings LLC
- Target
- Lantheus Holdings, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Buyer history
Altaris, LLC
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive